The New York State Psychiatric Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1895-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.nyspi.org
Clinical Trials
433
Active:5
Completed:306
Trial Phases
6 Phases
Early Phase 1:4
Phase 1:59
Phase 2:113
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (411 trials with phase data)• Click on a phase to view related trials
Not Applicable
141 (34.3%)Phase 2
113 (27.5%)Phase 4
76 (18.5%)Phase 1
59 (14.4%)Phase 3
18 (4.4%)Early Phase 1
4 (1.0%)A Multimodal Imaging Study of Dopamine in Early Psychosis
Phase 1
Not yet recruiting
- Conditions
- Clinical High Risk for Psychosis (CHR)
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 115
- Registration Number
- NCT06977308
Olfactory Training in Mild Cognitive Impairment
Not Applicable
Recruiting
- Conditions
- Mild Cognitive Impairment
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Jeffrey Motter
- Target Recruit Count
- 30
- Registration Number
- NCT06825403
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Exercise and Olanzapine-samidorphan
Phase 4
Recruiting
- Conditions
- Schizophenia DisorderSchizoaffective DisorderBipolar Disorder I or IIBipolar Disorder NOS
- Interventions
- Drug: Olanzapine-samidorphan + exercise
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06740890
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Mindfulness-Based Substance Use Prevention (MINDS-UP)
Not Applicable
Not yet recruiting
- Conditions
- Substance Use
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 45
- Registration Number
- NCT06593470
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06518941
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 87
- Next
News
Psilocybin Shows Promise in Reducing Symptoms of Body Dysmorphic Disorder
A pilot study indicates that psilocybin significantly reduced symptoms in individuals with body dysmorphic disorder (BDD).